Skip to content

Heart Health

LDL, HDL and Triglycerides: What Each Number Actually Tells You

LDL, HDL and triglycerides are grouped together on a lipid panel, but they represent different particles and different kinds of cardiovascular information.

Adult reviewing a cholesterol panel with a clinician

A standard lipid panel might show:

  • LDL: 132
  • HDL: 47
  • triglycerides: 168

They appear on the same report, but they are not three versions of the same thing.

LDL is about atherogenic particles

LDL stands for low-density lipoprotein.

Strictly speaking, LDL is a particle. LDL-C — the number usually reported — estimates how much cholesterol is being carried inside LDL particles.

Why does that matter?

ApoB-containing particles can enter the artery wall, become retained there, and participate in the development of:

atherosclerotic plaque.

The evidence that reducing LDL reduces cardiovascular events is extremely strong.

A large Cholesterol Treatment Trialists' analysis found that each reduction of about:

39 mg/dL in LDL cholesterol

was associated with roughly:

22% fewer major vascular events.

That is why LDL remains a major treatment target.

ApoB tells you something slightly different

Every major atherogenic lipoprotein particle carries one molecule of:

apolipoprotein B — ApoB.

ApoB therefore gives a closer estimate of the number of atherogenic particles, while LDL-C tells you how much cholesterol is carried inside a subset of them.

The two often agree, but they can diverge — particularly when triglycerides are elevated or insulin resistance is present.

HDL is not simply “good cholesterol”

HDL stands for high-density lipoprotein.

Higher HDL levels have long been associated with lower cardiovascular risk.

That led to the simple story:

LDL is bad. HDL is good.

But drugs designed specifically to raise HDL have not reliably reduced cardiovascular events.

That tells us HDL is not a mirror image of LDL.

A low HDL can be a useful marker of risk, but simply forcing the number higher does not necessarily improve outcomes.

Triglycerides are different again

Triglycerides are the main form in which fat energy travels and is stored.

High triglycerides commonly occur with:

  • abdominal obesity
  • insulin resistance
  • diabetes
  • excess alcohol intake
  • certain medications
  • genetic conditions

Triglyceride-rich remnant particles can also contribute to atherosclerosis.

Very high triglycerides create another concern:

pancreatitis.

Levels of 500 mg/dL or higher deserve attention, and risk becomes especially concerning near or above 1,000 mg/dL.

Non-HDL cholesterol can add useful information

Non-HDL cholesterol is:

total cholesterol minus HDL cholesterol.

It captures cholesterol carried by all major atherogenic particles, not just LDL.

This can be especially useful when triglycerides are elevated.

Get the research, without the noise.

Practical, sourced writing on blood sugar and metabolic health. One email a week.

One email a week. Unsubscribe any time. See our privacy policy.

What about Lp(a)?

Lipoprotein(a), or Lp(a), is a genetically influenced ApoB-containing particle.

High Lp(a) is associated with greater risk of atherosclerotic cardiovascular disease and aortic valve disease.

Current guidelines increasingly support measuring it at least once in adulthood because levels are largely inherited and relatively stable.

A commonly used risk-enhancing threshold is around:

125 nmol/L or 50 mg/dL

depending on the assay.

The Health Facts takeaway

A lipid panel is not one cholesterol score split into three pieces.

LDL tells you about cholesterol carried in one of the major atherogenic particle classes.

ApoB estimates the number of atherogenic particles.

HDL is an important risk marker, but raising it artificially has not proven to reduce risk.

Triglycerides reflect a different part of fat transport and, at very high levels, can raise pancreatitis risk.

The goal is not to make every number look perfect.

It is to understand which numbers are actually driving risk.

Sources

  1. 1. ACC/AHA and collaborating organizations. Guideline on the Management of Dyslipidemia. doi:10.1161/CIR.0000000000001423
  2. 2. Cholesterol Treatment Trialists' Collaboration. Efficacy and Safety of More Intensive Lowering of LDL Cholesterol. The Lancet. doi:10.1016/S0140-6736(10)61350-5
  3. 3. Ference BA, et al. Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. European Heart Journal. doi:10.1093/eurheartj/ehx144
  4. 4. National Heart, Lung, and Blood Institute. Blood Cholesterol.
ShareFacebookX

Comments

No comments yet.

Leave a comment

Comments are moderated. Be kind and stay on topic.

Get the research, without the noise.

Practical, sourced writing on blood sugar and metabolic health. One email a week.

One email a week. Unsubscribe any time. See our privacy policy.